Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FUROSEMIDE vs ETHACRYNATE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Edema associated with heart failure, cirrhosis, renal disease,Hypertension,Hypercalcemia (off-label)
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema,Off-label: Adjunct in treatment of acute hypercalcemia
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Furosemide is primarily metabolized via glucuronidation (by UGT1A1, UGT1A9) and to a lesser extent by CYP450 enzymes (minor).
Primarily metabolized by hepatic glutathione S-transferase (GST) to a cysteine conjugate; minor metabolism via oxidation. Excreted in urine and bile.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
91-99% (primarily to albumin).
Approximately 95% bound, primarily to albumin.
0.1-0.2 L/kg; increased in neonates (0.2-0.4 L/kg) and disease states (e.g., heart failure, cirrhosis).
0.1-0.2 L/kg (small Vd, consistent with high protein binding and limited extravascular distribution).
Oral: 50-60% (variable, 10-100% range due to food and formulation); IM: 100% (relative to IV).
Oral: approximately 100% (well absorbed, no significant first-pass metabolism).
GFR 10-50 m L/min: dose unchanged; GFR <10 m L/min: avoid use or use with caution; anuric patients: contraindicated.
e GFR 30-59 m L/min: reduce dose by 50%; e GFR <30 m L/min: avoid use or use with extreme caution.
Child-Pugh A-B: no adjustment; Child-Pugh C: reduce dose by 50% and monitor response; increased risk of hypokalemia and volume depletion.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Oral: 1-2 mg/kg/dose every 6-12 hours; IV/IM: 1 mg/kg/dose every 6-12 hours; max dose: 6 mg/kg/dose. Not recommended in neonates unless critical.
1 mg/kg intravenously once daily; maximum 50 mg/day. Not recommended in neonates.
Start at lowest effective dose (e.g., 20 mg orally once daily); monitor electrolytes, renal function, and volume status closely; avoid excessive diuresis.
Start at 25 mg intravenously once daily; increase slowly due to increased risk of electrolyte disturbances and hypotension.
Furosemide is a potent diuretic; excessive diuresis may lead to profound electrolyte depletion, volume depletion, and circulatory collapse.
Ethacrynic acid (ethacrynate) can cause profound diuresis with water and electrolyte depletion; close medical supervision and dose titration are required.
Monitor for electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Risk of ototoxicity, especially with rapid infusion or concurrent use of other ototoxic drugs,Monitor renal function and blood pressure; caution in patients with severe hepatic cirrhosis or renal impairment,May cause photosensitivity, blood dyscrasias, and hypersensitivity reactions
May cause severe electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) and volume depletion,Ototoxicity, especially with rapid IV administration or in patients with renal impairment; may be irreversible,Hyperuricemia and gout,Hepatic coma can be precipitated in patients with cirrhosis or ascites,May increase risk of digoxin toxicity due to hypokalemia,Photosensitivity reaction possible
Anuria,Severe electrolyte depletion,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or precoma (relative)
Anuria,Hypersensitivity to ethacrynic acid or any component,Severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Hepatic coma or precoma
Avoid excessive salt intake to prevent fluid retention and counteract diuretic effect. Limit alcohol as it can increase diuretic effect and cause dehydration. May increase potassium loss; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated (e.g., with ACE inhibitors). No specific restrictions with grapefruit juice.
Avoid excessive intake of salt substitutes containing potassium unless advised by your doctor. Grapefruit juice may enhance diuretic effect; monitor for hypotension. Alcohol can increase diuretic effect and risk of hypotension. Caffeine may worsen electrolyte imbalance. Ensure adequate fluid intake unless fluid restriction is prescribed.
Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at high doses. Second/third trimesters: Risk of electrolyte imbalance in mother and fetus, potential for decreased placental perfusion due to maternal hypovolemia. Use only if benefit outweighs risk, especially in oligohydramnios or preeclampsia.
Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, ototoxicity, and oligohydramnios in the fetus due to diuretic effect. Avoid use in pregnancy unless clearly needed.
Furosemide is excreted into breast milk in low amounts (M/P ratio approximately 2.6). Theoretical risk of electrolyte imbalance in infant. Consider using lowest effective dose and monitor infant for signs of dehydration or electrolyte disturbances.
Excreted into breast milk in low concentrations; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., electrolyte imbalance, diuresis). Weigh benefits against risks; consider alternative diuretics.
Pregnancy increases renal clearance and volume of distribution, potentially reducing plasma furosemide levels, but dosing adjustments are not routinely recommended due to risk of hypovolemia. Use lowest effective dose and titrate based on response, with close monitoring.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, specific dose adjustments for ethacrynate sodium are not established. Use lowest effective dose and monitor for hypotension and electrolyte imbalances.
Monitor urine output and electrolytes, especially potassium. Avoid use in anuria, severe electrolyte depletion, and hepatic coma. Can cause ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Sulfonamide allergy may cross-react; use caution. Loop diuretics like furosemide are effective in renal impairment, unlike thiazides.
Ethacrynate sodium is a loop diuretic used for patients with sulfonamide allergy as it is not a sulfonamide derivative. Monitor for ototoxicity, especially in patients with renal impairment or when used with other ototoxic drugs. Rapid IV administration can cause severe hypotension; infuse slowly over several minutes. Hypokalemia and hypomagnesemia are common; monitor electrolytes and consider potassium-sparing diuretic or supplementation. Ethacrynic acid can cause GI bleeding; use with caution in peptic ulcer disease.
Take exactly as prescribed, preferably in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and NSAIDs as they may reduce diuretic effect or increase kidney damage.,Report hearing loss, ringing in ears, dizziness, or muscle cramps immediately.,Do not stop suddenly without consulting your doctor; may cause rebound edema.,Limit high-potassium foods if also taking ACE inhibitors or potassium-sparing diuretics.,Stay hydrated but avoid excessive fluid intake.
Take this medication exactly as prescribed, usually once or twice daily.,You may need to urinate frequently; take your last dose of the day early to avoid nighttime urination.,Avoid alcohol and limit salt intake to help reduce fluid retention.,Report any hearing loss, ringing in the ears, or dizziness to your healthcare provider immediately.,Eat potassium-rich foods like bananas, oranges, or potatoes unless directed otherwise by your doctor.,Weigh yourself daily and report sudden weight gain or loss to your healthcare provider.,Do not take any over-the-counter medications, especially NSAIDs, without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Zaltoprofen, a nonsteroidal anti-inflammatory drug (NSAID), reduces the antihypertensive and diuretic efficacy of furosemide by inhibiting renal prostaglandin synthesis. This blockade diminishes renal blood flow and natriuretic response, potentially leading to fluid retention and diminished blood pressure control. The interaction may precipitate or exacerbate heart failure and edema in susceptible patients."
"Isoflurane, a halogenated inhalational anesthetic, can cause dose-dependent myocardial depression and systemic vasodilation, leading to decreased blood pressure and renal perfusion. Furosemide, a loop diuretic, further reduces intravascular volume and renal blood flow via inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. Co-administration may result in additive hypotension, acute kidney injury, and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia), particularly in patients with pre-existing renal impairment or hemodynamic instability."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FUROSEMIDE vs ETHACRYNATE SODIUM, answered by our medical review team.
FUROSEMIDE is a Loop Diuretic that works by Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.. ETHACRYNATE SODIUM is a Loop Diuretic that works by Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FUROSEMIDE and ETHACRYNATE SODIUM depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FUROSEMIDE is: Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.. The standard adult dose of ETHACRYNATE SODIUM is: 50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FUROSEMIDE and ETHACRYNATE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FUROSEMIDE is classified as Category A/B. Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at . ETHACRYNATE SODIUM is classified as Category C. Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, oto. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.